Video

Dr. Hashem El-Serag on the Relationship Between NASH and HCC

Hashem El-Serag, MD, MPH, medicine-gastroenterology, Baylor College of Medicine, discusses the relationship between nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC).

Hashem El-Serag, MD, MPH, medicine-gastroenterology, Baylor College of Medicine, discusses the relationship between nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC).

NASH is a condition of where the liver has both fat, inflammation, and scar tissue or fibrous. There is increasing evidence that this condition can lead to HCC, predominantly through the formation of cirrhosis. Nonalcoholic fatty liver disease (NAFLD) by itself is weakly associated with HCC, but NASH, which is a more progressed form of NAFLD, has a higher risk of HCC, around 5% over 20 years of follow-up. Patients that have NASH-related cirrhosis have a much more measurable risk of 1% per year of developing HCC, says El-Serag. Most experts would recommend routine surveillance for HCC for this patient population.

There needs to be more education regarding the association between NASH and HCC, says El-Serag. The vast majority of HCC cases that get diagnosed and the underlining cause is NASH are not recognized as having cirrhosis prior to their diagnosis. Most of them have not undergone routine surveillance and screening. This lack of knowledge is highly disproportionate to the other causes of cirrhosis.

Related Videos
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center